Sun Nelson sold $395K of AARD

Oppenheimer downgraded Aardvark Therapeutics (NASDAQ:AARD) to Perform, withdrawing its $21 price target. The stock fell 63% to $0.98, near its 52-week low, after mixed Phase 3 study results. The company plans to seek FDA feedback on a revised study design and resume clinical activities in 2027. H.C. Wainwright also lowered its price target to $2, citing ongoing challenges.

Aardvark Therapeutics (AARD) reported exploratory data from its terminated Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome (PWS). The FDA lifted the clinical hold, and the company plans to seek guidance for a new Phase 3 trial, targeting 2027. ARD-101 showed modest efficacy in reducing hyperphagia but requires further study. AARD stock is down 48.67% year-to-date.

Aardvark reported exploratory data from the ARD-101 trial, showing reductions in hyperphagia scores. The FDA lifted the clinical hold on ARD-101, and the company plans to seek FDA input on a new Phase 3 trial, expecting to resume clinical activities in 2027. The trial showed modest efficacy and was generally well tolerated.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials • HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory • HQ-CT scores fell by Week 2 of dose escala

Aardvark Therapeutics (NASDAQ:AARD) reported exploratory data from its terminated Phase 3 HERO trial for ARD-101, a treatment for Prader-Willi syndrome. The trial was stopped early with 67 participants. HQ-CT scores improved during treatment but rebounded after stopping. ARD-101 was generally well-tolerated, with one serious adverse event linked to a drug interaction.

Aardvark Therapeutics (AARD) halted its Phase 3 HERO trial early, reporting exploratory data showing modest reductions in HQ-CT scores for ARD-101, a hunger-suppressing drug for Prader-Willi syndrome (PWS). Scores rebounded near baseline post-treatment. The FDA lifted its clinical hold, and Aardvark plans to meet with the FDA to design a new Phase 3 trial, aiming to resume PWS clinical activities in 2027. ARD-101 was generally well-tolerated, with mild to moderate adverse events.